Category Archives: Warning Letters

DTC and Regulatory Enforcement

FDA’s OPDP views nearly all industry communication – whatever the venue and intent – through a lens of advertising.  Certainly a big focus of regulatory enforcement has been direct-to-consumer advertising and for a long time, there has been guidance available … Continue reading

Posted in Warning Letters | 4 Comments

Warning and Untitled Letters By Therapeutic Category – Oncology

Ever since developing a data base on the Office of Prescription Drug Promotion (OPDP) Warning and Untitled letters, I have wanted to sort the information along various lines to see differences and similarities given different circumstances.  Last year, I produced … Continue reading

Posted in Warning Letters | Comments Off

Warning and NOV Letter Summary – 1st Quarter 2014

Each quarter, I provide an overview of the most recent Warning and NOV letters from OPDP to gain insight into any lessons learned and to look at overall trends.  But this quarter, it is really slim pickings.  More than slim … Continue reading

Posted in Warning Letters | 1 Comment

OPDP Issues Untitled Letter Involving Social Media

Sort of. There is, of course, a difference between a regulatory action letter that is issued because of a social media use and a regulatory action letter that is issued the communication happens to involve a social media platform.  In … Continue reading

Posted in Social Media, Warning Letters | 1 Comment

Warning and NOV Letter Summary – 4th Quarter 2013

I usually wait a little bit longer after the end of the quarter to write up a summary of letters issued by the Office of Prescription Drug Promotion (OPDP) because there can sometimes be a healthy lag time between the … Continue reading

Posted in Warning Letters | 1 Comment